Literature DB >> 11169448

Long lasting p53-specific T cell memory responses in the absence of anti-p53 antibodies in patients with resected primary colorectal cancer.

S H van der Burg1, K de Cock, A G Menon, K L Franken, M Palmen, A Redeker, J Drijfhout, P J Kuppen, C van de Velde, L Erdile, R A Tollenaar, C J Melief, R Offringa.   

Abstract

Colorectal carcinoma is commonly associated with mutation and overexpression of p53, making this antigen a potential target for immune intervention. We analyzed humoral and proliferative immunity against p53 in the blood of patients with resected primary colorectal cancer. The majority of these patients displayed anti-p53 T helper (Th) immunity in the absence of measurable p53 specific antibody levels. The Th responses were long-lasting since they could be detected up to several years after resection of the primary tumor. In a number of cases the Th responses were highly sensitive, reflected by the recognition of naturally processed p53 protein. Our data argue that boosting of these responses in patients with minimal residual disease through p53-specific vaccination, may be employed for improving the chance of disease-free survival of these patients.

Entities:  

Mesh:

Substances:

Year:  2001        PMID: 11169448     DOI: 10.1002/1521-4141(200101)31:1<146::aid-immu146>3.0.co;2-t

Source DB:  PubMed          Journal:  Eur J Immunol        ISSN: 0014-2980            Impact factor:   5.532


  13 in total

Review 1.  Translating p53 into the clinic.

Authors:  Chit Fang Cheok; Chandra S Verma; José Baselga; David P Lane
Journal:  Nat Rev Clin Oncol       Date:  2010-10-26       Impact factor: 66.675

2.  Selective unresponsiveness to beta cell autoantigens after induction immunosuppression in pancreas transplantation with anti-interleukin-2 receptor antibody versus anti-thymocyte globulin.

Authors:  P van de Linde; P J M Vd Boog; O M H Tysma; J F Elliott; D L Roelen; F H J Claas; J W de Fijter; B O Roep
Journal:  Clin Exp Immunol       Date:  2007-04-25       Impact factor: 4.330

3.  p53-Reactive T Cells Are Associated with Clinical Benefit in Patients with Platinum-Resistant Epithelial Ovarian Cancer After Treatment with a p53 Vaccine and Gemcitabine Chemotherapy.

Authors:  Nicola R Hardwick; Paul Frankel; Christopher Ruel; Julie Kilpatrick; Weimin Tsai; Ferdynand Kos; Teodora Kaltcheva; Lucille Leong; Robert Morgan; Vincent Chung; Raechelle Tinsley; Melissa Eng; Sharon Wilczynski; Joshua D I Ellenhorn; Don J Diamond; Mihaela Cristea
Journal:  Clin Cancer Res       Date:  2018-01-04       Impact factor: 12.531

4.  TP53 missense mutation is associated with increased tumor-infiltrating T cells in primary prostate cancer.

Authors:  Harsimar B Kaur; Jiayun Lu; Liana B Guedes; Laneisha Maldonado; Logan Reitz; John R Barber; Angelo M De Marzo; Scott A Tomlins; Karen S Sfanos; Mario Eisenberger; Edward M Schaeffer; Corinne E Joshu; Tamara L Lotan
Journal:  Hum Pathol       Date:  2019-03-06       Impact factor: 3.466

5.  The cholesterol metabolite 27-hydroxycholesterol regulates p53 activity and increases cell proliferation via MDM2 in breast cancer cells.

Authors:  Shaneabbas Raza; Joyce E Ohm; Archana Dhasarathy; Jared Schommer; Conor Roche; Kimberly D P Hammer; Othman Ghribi
Journal:  Mol Cell Biochem       Date:  2015-09-08       Impact factor: 3.396

Review 6.  Pharmacological activation of p53 in cancer cells.

Authors:  Mohammad Athar; Craig A Elmets; Levy Kopelovich
Journal:  Curr Pharm Des       Date:  2011       Impact factor: 3.116

7.  CD4+ T cell responses to HLA-DP5-restricted wild-type sequence p53 peptides in patients with head and neck cancer.

Authors:  Kazuaki Chikamatsu; Koichi Sakakura; Goro Takahashi; Atsushi Okamoto; Nobuhiko Furuya; Theresa L Whiteside; Albert B DeLeo; Keisuke Masuyama
Journal:  Cancer Immunol Immunother       Date:  2009-01-28       Impact factor: 6.968

8.  Survey of naturally occurring CD4+ T cell responses against NY-ESO-1 in cancer patients: correlation with antibody responses.

Authors:  Sacha Gnjatic; Djordje Atanackovic; Elke Jäger; Mitsutoshi Matsuo; Annamalai Selvakumar; Nasser K Altorki; Robert G Maki; Bo Dupont; Gerd Ritter; Yao-Tseng Chen; Alexander Knuth; Lloyd J Old
Journal:  Proc Natl Acad Sci U S A       Date:  2003-07-09       Impact factor: 11.205

9.  Humoral immune response to p53 correlates with clinical course in colorectal cancer patients during adjuvant chemotherapy.

Authors:  Mirna Lechpammer; Josip Lukac; Stanislav Lechpammer; Dujo Kovacević; Massimo Loda; Zvonko Kusić
Journal:  Int J Colorectal Dis       Date:  2003-11-21       Impact factor: 2.571

Review 10.  The role of p53 in the immunobiology of cutaneous squamous cell carcinoma.

Authors:  A P B Black; G S Ogg
Journal:  Clin Exp Immunol       Date:  2003-06       Impact factor: 4.330

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.